Innovative approaches that exploit the unique molecular characteristics of synovial sarcoma, such as targeting SS18-SSX fusion gene-related pathways, epigenetic modifications, and immunomodulation, offer a compelling avenue for therapeutic innovation, but it remains elusive if these will demonstrate clinical benefit and result in regulatory approvals for this rare indication [30,31]. The gene discussed is SSX2; the disease is synovial sarcoma.